Breaking News Instant updates and real-time market news.

BA

Boeing

$199.03

2.59 (1.32%)

, GE

General Electric

$28.92

-0.08 (-0.28%)

12:41
06/19/17
06/19
12:41
06/19/17
12:41

On The Fly: Top stock stories at midday

Stocks opened higher and continued to extend their gains in the first hour of trading before leveling off. The tech sector, which was beaten down last week, is leading the way today, with the Nasdaq on pace for its best day in three months. With today's strength, the Dow has hit another new all-time high as well. ECONOMIC EVENTS: In the U.S., no market moving economic data was released. In Europe, Emmanuel Macron's party secured a solid majority in the French parliament, although this was largely expected. Also, the U.K. and EU commenced formal Brexit negotiations. COMPANY NEWS: Shares of Boeing (BA) are up about 1% after the company made a number of announcements to kick off the Paris Air Show, including the official launch of the 737 MAX 10 as the newest member of the 737 MAX family. Also as part of the start of that event, GE Capital Aviation Services (GE) and Caisse de depot et placement du Quebec announced that they have signed a commitment letter to create a $2B global aircraft financing platform, to be named Einn Volant Aircraft Leasing... EQT Corporation (EQT) announced a definitive merger agreement to acquire all of the outstanding shares of and Rice Energy (RICE) common stock for total consideration of approximately $6.7B in cash and stock. EQT will also assume or refinance approximately $1.5B of net debt and preferred equity. After the deal news, EQT shares are down about 8% while Rice shares have jumped over 26%. MAJOR MOVERS: Among the notable gainers was Novadaq Technologies (NVDQ), which nearly doubled after the company agreed to be acquired by Stryker (SYK) for $11.75 per share in cash, implying a total equity value of approximately $701M. Also higher was Clovis Oncology (CLVS), which gained 48% after the company this morning announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival in certain types of ovarian cancer patients. The good news for Clovis sunk shares of its competitor Tesaro (TSRO), though the stock is well off its worst levels. Near noon Tesaro was down 1% as several analysts noted that the results for Clovis' PARP inhibitor Rubraca "were broadly similar" to that seen in Tesaro's Nova trial of Zejula. Among the other noteworthy losers was Rice Midstream Partners (RMP), which dropped 26% and was downgraded at several firms based on the implications of EQT's deal to acquire its sponsor Rice Energy. INDEXES: Near midday, the Dow was up 114.06, or 0.53%, to 21,498.34, the Nasdaq was up 73.92, or 1.2%, to 6,225.68, and the S&P 500 was up 16.96, or 0.7%, to 2,450.11.

BA

Boeing

$199.03

2.59 (1.32%)

GE

General Electric

$28.92

-0.08 (-0.28%)

EQT

EQT Corporation

$54.12

-4.65 (-7.91%)

RICE

Rice Energy

$24.86

5.17 (26.26%)

RMP

Rice Midstream

$18.01

-6.35 (-26.07%)

NVDQ

Novadaq

$6.00

-0.05 (-0.83%)

SYK

Stryker

$141.77

-0.47 (-0.33%)

CLVS

Clovis

$59.97

0.27 (0.45%)

TSRO

Tesaro

$144.31

0.08 (0.06%)

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

  • 30

    Jun

  • 02

    Oct

BA Boeing
$199.03

2.59 (1.32%)

05/22/17
LEHM
05/22/17
NO CHANGE
Target $200
LEHM
Overweight
Boeing price target raised to $200 from $190 at Barclays
Barclays analyst Carter Copeland raised his price target for Boeing to $200 saying the company "possesses significant margin expansion potential" in the coming years. Investors are unwilling to believe in Boeing's margin expansion potential, Copeland tells investors in a research note. He keeps an Overweight rating on the shares.
05/10/17
COWN
05/10/17
NO CHANGE
COWN
Boeing 737 MAX engine issue likely very short-term and correctable, says Cowen
Cowen said the Boeing 737 MAX engine issue appears to be a very short-term "blip" and correctable. The firm's analyst doesn't think its a serious concern because Boeing still expects to deliver the first 737 MAX this month and the engine "problem" is not a design shortfall but what appears to be an easily fixable sub-tier supplier component problem.
05/09/17
UBSW
05/09/17
UPGRADE
Target $63
UBSW
Buy
Spirit AeroSystems upgraded to Buy from Neutral at UBS
UBS analyst David Strauss upgraded Spirit AeroSystems to Buy citing a favorable risk/reward following the recent pullback in the shares. The selloff reflects concerns around Spirit's pricing negotiations with Boeing (BA), Strauss tells investors in a research note. The analyst believes current share levels reflect a 35% decline in legacy 737/777 cash, which is well below his forecast. He his price target for Spirit AeroSystems remains $63.
06/05/17
SBSH
06/05/17
NO CHANGE
Target $70
SBSH
Buy
Citi sees path for Spirit AeroSystems hitting $85/share
Spirit AeroSystems (SPR) is trading near its all-time deepest earnings discount versus Boeing (BA) despite Spirit generating better financial results, Citi analyst Jason Gursky tells investors in a research note. While the protracted Boeing negotiation is an overhang, it is already reflected in the multiple, the analyst argues. He highlights Spirit's improving cash flow, balance sheet flexibility, shareholder-friendly cash deployment and new growth opportunities. He sees a path to $85 per share "over time" and reiterates a Buy rating on the shares with a one-year target of $70.
GE General Electric
$28.92

-0.08 (-0.28%)

06/13/17
STFL
06/13/17
NO CHANGE
STFL
New General Electric CEO likely pleases investors, says Stifel
Stifel analyst Robert McCarthy says that investors were probably more pleased with GE's new CEO, John Flannery, than they would have been with either of the other two candidates- GE Power CEO Steve Bolze and CFO Jeff Bornstein. Flannery is viewed as more willing to make major changes than Bolze and is seen as not being as tied to the outgoing CEO as Bornstein, according to McCarthy. The analyst reiterates a $33 price target and a Buy rating on the stock.
05/25/17
DBAB
05/25/17
NO CHANGE
Target $24
DBAB
Sell
GE officially walked away from 2018 EPS target, says Deutsche Bank
Deutsche Bank analyst John Inch says General Electric CEO Jeff Immelt at a conference yesterday officially walked away from the company's $2.00-plus earnings per share framework for 2018 citing tougher markets. While investors had expected GE to abandon the $2.00-plus target, the company kept $2.00 per share at the high end of its 2018 framework, Inch tells investors in a research note. He believes $2.00 to be unrealistic, even as just a high point in the range. The analyst sees cash flow pressures continuing in 2018 and keeps a Sell rating on GE with a $24 price target.
05/31/17
DBAB
05/31/17
NO CHANGE
Target $24
DBAB
Sell
General Electric setting stage for dividend cut, says Deutsche Bank
Deutsche Bank analyst John Inch believes the stage is being set for General Electric to cut its common dividend. The analyst has a Sell rating on the shares with a $24 price target. Last Wednesday at a conference, GE provided a cash flow walk for the next two years that suggests it is likely to generate insufficient free cash flow to cover its common dividend this year, and barely enough next year, Inch tells investors in a research note. He believes a "reasonable dividend payout" on a future earnings reset could result in a GE dividend cut to 65c-75c. A dividend reduction could be part of an earnings "reset" lower and possibly in conjunction with eventual future leadership change, Inch writes.
06/01/17
FBCO
06/01/17
NO CHANGE
Target $34
FBCO
Outperform
General Electric has reached attractive entry point, says Credit Suisse
Credit Suisse analyst Julian Mitchell thinks the pendulum of investor sentiment regarding General Electric has swung too far in the negative direction, creating an attractive entry point into the stock. GE's organic growth seems underappreciated, argues Mitchell, who notes that its organic sales growth has topped most Electrical Equipment and Multi-Industry peers in recent years and into 2017. Meanwhile, GE's segments have shown "fairly healthy" operating leverage, added Mitchell, who has an Outperform rating and $34 price target on GE shares.
EQT EQT Corporation
$54.12

-4.65 (-7.91%)

06/19/17
RBCM
06/19/17
NO CHANGE
RBCM
RBC says EQT deal positive for EQT Midstream, negative for Rice Midstream
After EQT (EQT) announced an agreement to acquire Rice Energy (RICE), RBC Capital analyst TJ Schultz called the news a positive for EQT Midstream (EQM) and EQT GP (EQGP), as it will enhance their growth outlook. However, he views it as a near-term negative for Rice Midstream (RMP), which now lacks clarity and no longer has drops to support growth. Schultz added that he thinks EQT eventually will look to collapse the midstream structure to eliminate the IDRs.
03/13/17
TUDR
03/13/17
UPGRADE
TUDR
Buy
EQT Corporation upgraded to Buy from Hold at Tudor Pickering
Tudor Pickering analyst Jeoffrey Lambujon upgraded EQT Corporation to Buy.
03/23/17
STFL
03/23/17
INITIATION
STFL
Buy
EQT Corporation coverage resumed with a Buy at Stifel
Stifel analyst Karl J. Chalabala resumed coverage of EQT with a $63 price target and a Buy rating. The analyst says that the company has the highest leverage to coming natural gas price increases.
05/02/17
STFL
05/02/17
NO CHANGE
STFL
EQT Corporation weakness overdone, says Stifel
Stifel analyst Karl Chalabala says that the decline in EQT's stock following its Q2 results are overdone. Despite the company's lower than expected quarterly production guidance, the analyst raised his estimates, citing "higher well productivity from increased type curves and forward gas strips continuing to grind higher." He raised his price target on the stock to $81 from $63 and keeps a Buy rating on the shares.
RICE Rice Energy
$24.86

5.17 (26.26%)

03/23/17
STFL
03/23/17
INITIATION
STFL
Buy
Rice Energy coverage resumed with a Buy at Stifel
Stifel analyst Karl J. Chalabala resumed coverage of Rice with a $32 price target and a Buy rating.
02/06/17
GHSC
02/06/17
UPGRADE
GHSC
Buy
Rice Energy upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Mike Kelly upgraded Rice Energy to Buy with a $28 price target citing compelling NAV upside and continued operational improvements.
03/31/17
GHSC
03/31/17
DOWNGRADE
Target $26
GHSC
Neutral
Rice Energy downgraded to Neutral from Buy at Seaport Global
Seaport Global analysts led by Mike Kelly downgraded Rice Energy to Neutral from Buy and and lowered its price target to $26 from $28. Kelly said Rice has limited upside relative to his $2.50/Mcf long-term gas estimate and valuation is inline with peers.
RMP Rice Midstream
$18.01

-6.35 (-26.07%)

06/19/17
JRCO
06/19/17
DOWNGRADE
JRCO
Hold
Rice Midstream downgraded to Hold from Buy at Johnson Rice
06/19/17
RHCO
06/19/17
DOWNGRADE
RHCO
Hold
Rice Midstream downgraded to Hold from Buy at SunTrust
06/19/17
WELS
06/19/17
DOWNGRADE
WELS
Market Perform
Rice Midstream downgraded to Market Perform from Outperform at Wells Fargo
NVDQ Novadaq
$6.00

-0.05 (-0.83%)

06/01/17
STFL
06/01/17
NO CHANGE
STFL
Aetna may now cover Novadaq's DermACELL, says Stifel
03/13/17
NORL
03/13/17
UPGRADE
Target $7
NORL
Market Perform
Novadaq upgraded to Market Perform from Underperform at Northland
Northland analyst Suraj Kalia upgraded Novadaq Technologies to Market Perform saying the stock is in "relative equilibrium." The analyst keeps a $7 price target for the shares.
03/01/17
FLTL
03/01/17
DOWNGRADE
FLTL
Hold
Novadaq downgraded to Hold from Buy at Feltl
Feltl downgraded Novadaq to Hold and lowered its price target to $7 from $8.75 citing increased uncertainty and lack of near-term catalysts following the Q4 report and guidance.
06/19/17
WEDB
06/19/17
DOWNGRADE
WEDB
Neutral
Novadaq downgraded to Neutral from Outperform at Wedbush
Novadaq (NVDQ) is being acquired by Stryker (SYK) for $11.75 per share in cash.
SYK Stryker
$141.77

-0.47 (-0.33%)

05/23/17
MSCO
05/23/17
NO CHANGE
MSCO
Medtech Technology sector upgraded to Attractive from In-Line at Morgan Stanley
Morgan Stanley upgraded the Medtech Technology sector to Attractive saying structural fundamentals have improved and recent acceleration will likely continue, driving further multiple expansion.
05/24/17
NEED
05/24/17
NO CHANGE
NEED
Hold
Medtronic unlikely to buy Mazor Robotics in near-term, says Needham
Needham analyst Mike Matson attributes some of the year-to-date advance in shares of Mazor Robotics (MZOR) to speculation that Medtronic (MDT) will acquire the company, though he sees that as unlikely in the near-term. Mazor shares are now trading "well above" the multiple that Stryker (SYK) paid to acquire Mako, noted Matson, who thinks its possible that Medtronic could eventually buy Mazor but only if the multiple declines via either a lower stock price or higher revenue. He keeps a Hold rating on Mazor shares.
06/07/17
SBSH
06/07/17
NO CHANGE
Target $130
SBSH
Neutral
Citi ups Zimmer price target following orthopedic surgeon survey
After surveying 30 Biomet-specific orthopedic surgeons who experienced some supply shortages since Q3 of 2016, Citi analyst Amit Hazan sees a higher probability that Zimmer Biomet (ZBH) returns to full supply by end of the summer and begins to regain lost market share. The survey also showed that about half of Zimmer's supply-related share loss has gone to Stryker (SYK), Hazan tells investors in a research note. With the share gains expected to reverse, the analyst expects Stryker's U.S. knee growth to slow in the second half of 2017. He notes consensus expectations have the company's knee growth accelerating in the back half of the year due to MAKO. Hazan raised his price target for Stryker to $125 from $114 citing higher group valuations but keeps a Sell rating on the shares. To reflect an improved outlook, the analyst raised his price target for Zimmer to $130 from $108. He keeps a Neutral rating on the shares.
06/13/17
LEER
06/13/17
NO CHANGE
Target $158
LEER
Outperform
Stryker price target raised to $158 from $151 at Leerink
Leerink analyst Richard Newitter raised his price target for Stryker to $158 after hosting an investor dinner with management. The analyst believes the company has "multiple sales growth drivers across a diversified set of businesses." His new price target reflects group multiple expansion and he keeps an Outperform rating on the name.
CLVS Clovis
$59.97

0.27 (0.45%)

06/19/17
RAJA
06/19/17
NO CHANGE
RAJA
Market Perform
Raymond James remains cautious on Tesaro, takeout less likely
Raymond James analyst Christopher Raymond remains cautious on Tesaro (TSRO) shares following Clovis' (CLVS) Rubraca ARIEL3 results. The analyst said PFS measures between the Clovis Rubraca and Tesaro's Zejula are remarkably similar among ovarian cancer patients, making the PARP space much more competitive and crowded. Raymond believes a takeout of Tesaro based on Zejula's superior labeling is much less likely and reiterated his Market Perform rating on shares.
06/19/17
JEFF
06/19/17
NO CHANGE
Target $124
JEFF
Hold
Tesaro worth $80 per share on fundamentals, says Jefferies
Jefferies analyst Eun Yang views Clovis Oncology's (CLVS) data today for rucaparib as "highly competitive" to Tesaro's (TSRO) niraparib. The data from Clovis will likely impact any potential takeover premium for Tesaro, Yang tells investors in a research note. The analyst views Tesaro as being worth $80 per share on a fundamental basis. She has a Hold rating and $124 price target on the shares. Tesaro in early trading is down 5%, or $7.09, to $137.22.
06/19/17
06/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Neutral from Sell at UBS with analyst Carter Gould saying he sees an improved risk/reward and a positive near-term setup going into the second quarter earnings call and strategic review. 2. Clovis (CLVS) upgraded to Neutral from Sell at Chardan. 3. Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Christopher Prykull saying early season indicators appear strong as several management teams noted ongoing leisure strength at the firm's Lodging, Gaming Restaurant and Leisure Conference. 4. Athene Holding (ATH) upgraded to Outperform from Neutral at Credit Suisse with analyst John Nadel saying he believes the probability is increasing that Athene will use acquisitions to accelerate its balance sheet and earnings growth. 5. Credit Suisse (CS) upgraded to Buy from Hold at Deutsche Bank with analyst Kinner Lakhani saying an inflection in the company's operating results is near following the recent anticipated capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/17
COWN
06/19/17
NO CHANGE
Target $125
COWN
Market Perform
Tesaro price target cut to $125 from $145 at Cowen
Cowen analyst Boris Peaker reduced Tesaro's (TSRO) price target to $125 from $145 following Clovis' report this morning that rucaparib's pivotal ARIEL3 study met its PFS endpoint. The analyst said that all three leading PARPs are largely undifferentiated and trimmed niraparib peak rates across all subgroups. The analyst rates Tesaro shares a Market Perform.
TSRO Tesaro
$144.31

0.08 (0.06%)

06/19/17
LEER
06/19/17
NO CHANGE
LEER
Market Perform
Clovis reported similar efficacy to Tesaro's Zejula, says Leerink
Leerink analyst Seamus Fernandez says the top-line efficacy data announced this morning for Clovis Oncology's (CLVS) Phase 3 Ariel3 trial of its PARP inhibitor Rubraca "were broadly similar" to that seen in Tesaro's (TSRO) Nova trial of Zejula across all patient population in second-line or greater ovarian cancer maintenance. This adds "considerable weight" to the argument that all three of these PARP inhibitors have similar activity, Fernandez tells investors in a research note. The analyst keeps a Market Perform rating on Tesaro shares.

TODAY'S FREE FLY STORIES

ICPT

Intercept

$98.12

1.92 (2.00%)

15:41
09/21/17
09/21
15:41
09/21/17
15:41
Recommendations
Intercept analyst commentary  »

Intercept selloff an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$172.17

-0.35 (-0.20%)

15:39
09/21/17
09/21
15:39
09/21/17
15:39
Hot Stocks
Facebook says will help government in ' vitally important ' election probe »

The company said the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

15:38
09/21/17
09/21
15:38
09/21/17
15:38
Hot Stocks
Sanderson Farms up regular dividend to 32c, declares special dividend of $1.00 »

Sanderson Farms announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

15:36
09/21/17
09/21
15:36
09/21/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Sanderson Farms »

Sanderson Farms declares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFM

Sanderson Farms

$162.06

1.5 (0.93%)

15:36
09/21/17
09/21
15:36
09/21/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Sanderson Farms »

Sanderson Farms raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIK

Michaels

$21.42

-0.03 (-0.14%)

15:30
09/21/17
09/21
15:30
09/21/17
15:30
Options
Bullish flow continues for a third day in Michaels Companies »

Bullish flow continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
09/21/17
09/21
15:17
09/21/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
09/21/17
09/21
15:16
09/21/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
09/21/17
09/21
15:15
09/21/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

15:10
09/21/17
09/21
15:10
09/21/17
15:10
General news
Fedspeak is heavy next week, with 12 Committee members scheduled »

Fedspeak is heavy next…

CSX

CSX

$52.81

1.03 (1.99%)

15:05
09/21/17
09/21
15:05
09/21/17
15:05
Hot Stocks
CSX says service 'rapidly' restored following Hurricane Irma »

CSX said that following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 29

    Oct

  • 30

    Oct

GE

General Electric

$24.65

0.33 (1.36%)

15:05
09/21/17
09/21
15:05
09/21/17
15:05
Options
General Electric call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ICPT

Intercept

$98.12

1.92 (2.00%)

15:00
09/21/17
09/21
15:00
09/21/17
15:00
Downgrade
Intercept rating change  »

Intercept downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$13.70

-0.46 (-3.25%)

14:57
09/21/17
09/21
14:57
09/21/17
14:57
Periodicals
Snap cuts headcount at hardware lab, maker of spectacles, Bloomberg says »

According to the report,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$43.73

-0.44 (-1.00%)

14:55
09/21/17
09/21
14:55
09/21/17
14:55
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

14:55
09/21/17
09/21
14:55
09/21/17
14:55
General news
Canada CPI preview »

Canada CPI preview: CPI,…

14:50
09/21/17
09/21
14:50
09/21/17
14:50
General news
Canada retail sales preview »

Canada retail sales…

ICPT

Intercept

$98.12

1.92 (2.00%)

14:49
09/21/17
09/21
14:49
09/21/17
14:49
Recommendations
Intercept analyst commentary  »

Citi calls FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
09/21/17
09/21
14:45
09/21/17
14:45
Conference/Events
Cowen retail analyst hold an analyst/industry conference call »

Retailing/Specialty…

PSTG

Pure Storage

$15.32

0.49 (3.30%)

14:45
09/21/17
09/21
14:45
09/21/17
14:45
Options
Pure Storage call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

NLSN

Nielsen

$40.48

0.06 (0.15%)

, CBS

CBS

$58.90

-0.155 (-0.26%)

14:44
09/21/17
09/21
14:44
09/21/17
14:44
Hot Stocks
CBS to use Nielsen Out-of-Home Reporting Service »

Nielsen (NLSN) announced…

NLSN

Nielsen

$40.48

0.06 (0.15%)

CBS

CBS

$58.90

-0.155 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

  • 02

    Nov

ALNY

Alnylam

14:41
09/21/17
09/21
14:41
09/21/17
14:41
Hot Stocks
Alnylam CEO 'confident' patisiran is best-in-class treatment »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESRX

Express Scripts

$61.82

0.82 (1.34%)

, NVS

Novartis

$85.01

-0.77 (-0.90%)

14:41
09/21/17
09/21
14:41
09/21/17
14:41
Hot Stocks
Express Scripts CMO discusses 'great promise, big price' of gene therapy »

In a post to the…

ESRX

Express Scripts

$61.82

0.82 (1.34%)

NVS

Novartis

$85.01

-0.77 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Oct

  • 08

    Nov

  • 17

    May

ALNY

Alnylam

$113.84

38.8 (51.71%)

14:40
09/21/17
09/21
14:40
09/21/17
14:40
Hot Stocks
Alnylam CEO says more confident in other trials after patisiran data »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTX

Minerals Technologies

$69.50

1.1 (1.61%)

14:33
09/21/17
09/21
14:33
09/21/17
14:33
Hot Stocks
Minerals Technologies authorizes $150M, two-year share repurchase program »

Minerals Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.